We work with Lupvindol to help advance safer treatment options for animal health.
Lupvindol Biosciences is developing investigational fixed-dose combination therapies aimed at reducing the side effects associated with long-term corticosteroid use in inflammatory and autoimmune conditions. Their programme includes active FDA Investigational New Animal Drug (INAD) filings targeting canine inflammatory bowel disease and equine osteoarthritis.
As an EpiVets partner, Lupvindol brings a research-driven approach to veterinary therapeutics, and we support the data and insights that help move promising treatments through the development pipeline.
Learn more about Lupvindol at lupvindol.com